Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases

C11348: Novel Anti-Angiogenic Collagen Derived Mimetic Peptides

Novelty:

modified peptides from collagen IV derived parent peptide Pentastatin-1

Value Proposition:

The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:

• Ability to inhibit adhesion and induction of apoptosis, two key components of angiogenesis.

• Posses anti-angiogenic properties such as inhibition of migration and tube formation.

• Potential to be developed as a therapeutic treatment option for a variety of angiogenic cancers.

• Proof of concept demonstrated in breast and lung cancer.

Technical Details:

Johns Hopkins researchers have synthesized modified peptide sequences derived from the parent peptide Pentastatin-1. The peptides generated were synthesized by solid phase synthesis and subjected to proliferation assay, migration assay, wound-healing assay, tube formation assay and tested in vivo through tumor xenograft inhibition in mouse models.

Looking for Partners:

To develop & commercialize the technology as a therapeutic for treatment of cancer by angiogenesis inhibition.

Stage of Development:

Pre-clinical

Data Availability:

Under CDA / NDA

Publications/Associated Cases:

Neoplasia. 2009 Dec; 11(12):1285-91 , BMC Cancer. 2010; 10: 29